Our News

08.04

2022

Press Release: Pharmathen’s 200 million euros investment plan, increased by 50 million euros for the next five years period 2022-2026

Press Release

Pharmathen’s 200 million euros investment plan, increased by 50 million euros for the next five years period 2022-2026

• Creation of a new hub for innovation in Attica
• 150 new job positions

In a meeting with the Prime Minister of Greece, Kyriakos Mitsotakis at the “Maximou” Palace, along with Charles Dallara, Chairman of the Board, Partners Group USA, Thomas Werner, President of the Supervisory BoD-Pharmathen, and Dimitris Kadis, CEO of Pharmathen, on Friday April 8th, was announced the increase of an additional 50 million euros in Pharmathen’s  200 million euros total investment program, which is now already in progress for the next five years 2022-2026.

Pharmathen, one of Europe's leading pharmaceutical companies and a leader in the field of complex Long Acting Injectable products (LAI), has immediate availability of the new fund of 50 million euros, for the creation of a new innovation hub in Attica,  which will be completed in 2025. The investment will benefit from Pharmathen's experience with Long Acting Injectables, as well as advanced technologies in ophthalmic products, enhancing the company's competitive edge in the international pharmaceutical market and creating at least 150 new jobs.

The design and construction of the new Pharmathen unit is based on the strict specifications of the EMA (European Medicines Agency) and the US-FDA (U.S. Food and Drug Administration). Pharmathen already has two modern state-of- the-art production units in Pallini, Attica and in Sapes, Rodopi and is the largest entity of private investing in the Research and Development sector in Greece and one of the largest in Europe.

Accurately devoted to the implementation of its development plan, part of which was the 250 million euros invested during the five years 2015-2021 creating 450 new jobs, Pharmathen plans to offer a total of 700 new jobs over the next five years.

Mr. Dimitris Kadis, CEO of Pharmathen, announced the following: "The increase of our investment plan by 50 million euros, practically proves the confidence that the management of the company and its shareholders have towards the country’s excellent scientists and potential. We remain committed to generating innovation and exporting innovative knowledge and information, investing in new technologies and products. "Together as a team with our 1,200 employees, we give our very best, every day to improve the lives of millions of people around the world."

Here you can view and download our official Press Release in Greek.

On the following link you can find the official announcement in Greek, as issued by the Prime Minister’s office: https://primeminister.gr/2022/04/08/29090.